Answers are grounded in this paper and cite their sources.
Plasma and cervicovaginal secretion (CVS) samples were collected from 19 human immunodeficiency virus type 1-infected women on lopinavir- or indinavir-containing regimens. Lopinavir and indinavir were detectable in 29 and 93% of CVS samples, respectively, a finding that may be ascribed to these drugs' differences in protein binding and pK(a). The relationship between lopinavir and indinavir pharmacodynamics and viral evolution in the female genital tract should be assessed over time.
No takes yet. Share an insight, caveat, or question.
Launay et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: